Potential mechanism of primary resistance to icotinib in patients with advanced non-small cell lung cancer harboring uncommon mutant epidermal growth factor receptor: A multi-center study.

Abstract

The incidence of epidermal growth factor receptor uncommon mutation (EGFRum) is relatively low and patients harboring EGFRum are resistant to the first-generation tyrosine kinase inhibitors (TKI). However, the mechanism of primary resistance remains unclear. Medical records of 98 patients who had never been treated by TKI and who accepted icotinib treatment were collected and followed. The circulating tumor DNA (ctDNA) were detected and analyzed using the next-generation sequencing (NGS) platform after progression on icotinib. The potential primary resistance mechanism of icotinib was explored. A total of 21 (21.4%) and 48 (49%) patients developed primary and acquired resistance to icotinib, respectively. The median progression-free survival (PFS) of primary resistance patients was 1.8 months (0.5-2.3, 95% CI = 1.50-2.10). Before treatment, 52.4% (11/21) of patients carried S768I, 23.8% (5/21) L861Q, 14.3% (3/21) G719X and 14.3% (3/21) exon 20-ins mutations. Approximately 23.8% (5/21) of patients harbored the combined pattern mutations and 76.2% (16/21) of patients harbored the single pattern mutations. The combined pattern with EGFR classical mutation (EGFRcm) had worse PFS than the combined with EGFRum and single pattern (P < .05). There were 6 (28.57%) patients with acquired EGFR extracellular domain mutation, 5 (23.81%) with BCL2L11 loss (BIM deletion polymorphism), 3 (14.29%) with MET amplification, 1 (4.76%) with ERBB2 amplification, 1 (4.76%) with MYC amplification, 1 (4.76%) with PTEN mutation, 1 (4.76%) with PIK3CA mutation and 3 (14.29%) with unknown status. EGFR extracellular domain mutation, BCL2L11 loss, PI3K-AKT-mTOR signaling pathway (PTEN and PIK3CA mutations), MET amplification, ERBB2 amplification or MYC amplification might contribute to molecular mechanisms of primary resistance to icotinib in patients with advanced non-small cell lung cancer harboring uncommon mutant epidermal growth factor receptor. Combined targeted therapy or chemotherapy should be considered in this population.

• Authors: Lei Lei, Wen-Xian Wang, You-Cai Zhu, Jin-Luan Li, Yong Fang, Hong Wang, Wu Zhuang, Yin-Bin Zhang, Li-Ping Wang, Mei-Yu Fang, Chun-Wei Xu, Xiao-Jia Wang, Tang-Feng Lv, Yong Song
• Journal: Cancer science (Cancer Sci) Vol. 111 Issue 2 Pg. 679-686 (Feb 2020) ISSN: 1349-7006 [Electronic] England
• PMID: 31828849 (Publication Type: Journal Article, Multicenter Study, Observational Study)
• Copyright: © 2019 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.

Chemical References

• Circulating Tumor DNA
• Crown Ethers
• Quinazolines
• icotinib
• EGFR protein, human
• ErbB Receptors

Topics

• Carcinoma, Non-Small-Cell Lung (drug therapy, genetics)
• China
• Circulating Tumor DNA (analysis)
• Crown Ethers (therapeutic use)
• Disease Progression
• Drug Resistance, Neoplasm
• ErbB Receptors (genetics)
• Female
• Gene Regulatory Networks
• High-Throughput Nucleotide Sequencing
• Humans
• Lung Neoplasms (drug therapy, genetics)
• Male
• Mutation
• Quinazolines (therapeutic use)
• Retrospective Studies
• Sequence Analysis, DNA